Home/Pipeline/Cancer Therapy Program

Cancer Therapy Program

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Young BioPharma

About Young BioPharma

Young BioPharma is an early-stage biotech leveraging natural product chemistry to discover new drugs for pain and oncology. The company boasts a seasoned leadership team with deep experience in drug development, including key contributors to the approved anticancer drug Halaven. With a proprietary library of over 10,000 natural products and multiple in-house assays, Young BioPharma is building a preclinical pipeline but operates as a private, pre-revenue entity facing significant development and funding risks inherent to the sector.

View full company profile

Therapeutic Areas

Pain Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active